Art

J-GLOBAL ID：201802260281710715   Reference number：18A1103421

Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study

糖尿病は慢性C型肝炎患者に対するインターフェロンフリーのソホスブビルベース療法中の血清アルブミンレベルの改善を阻止する:多施設共同研究

Author (11)： Kawano Akira (Department of Internal Medicine, Kitakyushu Municipal Medical Center, Japan) ,  Shigematsu Hirohisa (Department of Internal Medicine, Kitakyushu Municipal Medical Center, Japan) ,  Miki Koichiro (Department of Internal Medicine, Kitakyushu Municipal Medical Center, Japan) ,  Ichiki Yasunori (Department of Internal Medicine, Japan Community Health care Organization Kyushu Hospital, Japan) ,  Morita Chie (Department of Internal Medicine, JR Kyushu Hospital, Japan) ,  Yanagita Kimihiko (Department of Internal Medicine, Saiseikai Karatsu Hospital, Japan) ,  Takahashi Kazuhiro (Department of Medicine, Hamanomachi Hospital, Japan) ,  Dohmen Kazufumi (Department of Internal Medicine, Chihaya Hospital, Japan) ,  Nomura Hideyuki (The Center for Liver Disease, Shin-Kokura Hospital, Japan) ,  Ishibashi Hiromi (Department of Hepato-Biliary-Pancreatic Medicine, Fukuoka Sanno Hospital, Japan) ,  Shimoda Shinji (Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Japan)
Material： Internal Medicine (Web)  (Intern Med (Web))
Volume： 57  Issue： 11  Page： 1533-1542(J-STAGE)  Publication year： 2018 
JST Material Number： U0033A  ISSN： 1349-7235  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *direct acting antiviral agent

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1103421&from=J-GLOBAL&jstjournalNo=U0033A") }}

Author keywords (5)： Child-Pugh score ,  direct-acting antiviral drugs ,  interferon-free ,  non-alcoholic fatty liver disease ,  non-alcoholic steatohepatitis

JST classification (2)： Treatment for infectious diseases,parasitic diseases.  (GD01030D) ,  Drug therapy(=pharmacotherapy)for digestive system diseases  (GH05020G)

Substance index (3)： Sofosbuvir ,  Ribavirin ,  Ledipasvir

Reference (43)：

• 1. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28: 1687-1695, 1998.
• 2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001.
• 3. Ogawa E, Furusyo N, Kajiwara E, et al. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. J Gastroenterol Hepatol 27: 1233-1240, 2012.
• 4. De Clercq E. Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochem Pharmacol 89: 441-452, 2014.
• 5. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370: 1879-1888, 2014.

Terms in the title (9)： 糖尿病 ,  慢性C型肝炎 ,  患者 ,  インターフェロン ,  ソホスブビル ,  療法 ,  血清アルブミン ,  阻止 ,  多施設共同研究